سعر ايفرزين 6مجم 8 اقراص 2024

• Treatment of intestinal (non-disseminated) strongyloidiasis due to Strongyloides stercoralis.Population: Patients weighing 15 kg or moreDailyMed (U.S. National Library of Medicine)
• Treatment of onchocerciasis due to Onchocerca volvulus.Population: Patients weighing 15 kg or moreDailyMed (U.S. National Library of Medicine)

• In strongyloidiasis studies: dizziness, pruritus, diarrhoea and nausea (about 2-3%), and less often fatigue, abdominal pain, anorexia, constipation, vomiting, somnolence, vertigo, tremor, rash and urticaria.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Contraindicated in patients who are hypersensitive to any component of the product.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• In onchocerciasis, killing of microfilariae may cause cutaneous and/or systemic (Mazzotti-type) and ophthalmological reactions.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Neurotoxicity (altered consciousness from somnolence to stupor and coma, confusion, disorientation, and death) has been reported with ivermectin; reactions generally resolved with supportive care and stopping the drug.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Patients with onchocerciasis heavily infected with Loa loa may rarely develop serious or fatal encephalopathy after an effective microfilaricide.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• WarfarinIncreased INR has rarely been reported post-marketing when ivermectin was co-administered with warfarin.DailyMed (U.S. National Library of Medicine)

• Ivermectin was teratogenic in mice, rats and rabbits at or near maternotoxic doses; there are no adequate studies in pregnant women and it should not be used during pregnancy since safety has not been established.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Ivermectin is excreted in human milk in low concentrations; treat breastfeeding mothers only when the risk of delayed treatment to the mother outweighs the possible risk to the newborn.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

English text not available for this section.